WHO ICTRP trial
Efficacy and Safety of Vildagliptin as add-on Therapy to Insulin in Patients…
CTRI/2010/091/001276 · Clinical Trials Registry India (CTRI) · Not Recruiting
Key facts
| Trial ID | CTRI/2010/091/001276 |
|---|---|
| Public title | Efficacy and Safety of Vildagliptin as add-on Therapy to Insulin in Patients With Type 2 Diabetes Mellitus |
| Scientific title | A 24-week, multi-center, double-blind, randomized, placebo-controlled, parallel-group study to assess the efficacy and safety of vildagliptin 50mg bid as an add-on therapy to insulin, with or without metformin, in patients with type 2 diabetes mellitus - NIL |
| Primary sponsor | Novartis HeatlhCare Pvt Ltd |
| Registry | Clinical Trials Registry India (CTRI) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | Phase 3 |
| Countries | Australia;Belgium;Czech Republic;Germany;Hungary;India;Romania;Slovakia;United Kingdom |
| Conditions | Health Condition 1: null- Type 2 Diabetes Mellitus |
| Interventions | Intervention1: Vildagliptin: Experimental. Vildagliptin 50 mg tab bid, orally for 24weeks Control Intervention1: Placebo Comparator: Placebo. 501 tab (50mg)bid,given orally for a duration of 24weeks. |
| Registration date | Dec 22, 2010 |
| Target size | 428 |
| Secondary IDs | CLAF237A23135;NCT01224366 |
| Registry page | ctri.nic.in |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: